Synapse - Parag Patwardhan

Potent antitumor activity of MLN0128, an investigational selective mTORC1/2 kinase inhibitor, in preclinical models of rhabdomyosarcoma

Meeting Abstract

Slotkin, E.; Patwardhan, P.; Deraje, S. V. ; Schwartz, G.; Tap, W.
Cancer Research (2014)

Fulltext@MSK | Save

BIBF1120, an investigational triple angiokinase inhibitor, in combination with inhibitors of mTOR signaling shows potent antitumor activity in preclinical models of sarcoma

Meeting Abstract

Patwardhan, P. P.; Musi, E.; Ivy, K. S.; Giovino, N.; Schwartz, G. K.
Cancer Research (2014)

Fulltext@MSK | Save

Preclinical development of a novel multi-targeted kinase inhibitor, MG516, for the treatment of sarcoma

Meeting Abstract

Ivy, K. S.; Patwardhan, P. P.; Schwartz, G. K.
Cancer Research (2014)

Fulltext@MSK | Save

Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs

Journal Article

Patwardhan, P. P.; Surriga, O.; Beckman, M. J.; de Stanchina, E.; DeMatteo, R. P.; Tap, W. D.; Schwartz, G. K.
Clinical Cancer Research (2014)

Fulltext@MSK | Save

MLN0128, an investigational selective TORC1/2 kinase inhibitor, demonstrates potent antitumor activity in preclinical models of soft tissue sarcoma